Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | THRA | P10827 | 3/20 | 0.49 |
| ▸ | THRB | P10828 | 3/20 | 0.49 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16050416 | 0.93 | GPR84 (0.72) | PTGS2CYP3A4GPR84ALDH1A1HPGD | |
| SCHEMBL16050407 | 0.91 | ALDH1A1 (0.70) | PTGS2CYP3A4GPR84ALDH1A1HPGD | |
| SCHEMBL22040784 | 0.91 | ALDH1A1 (0.70) | PTGS2CYP3A4GPR84ALDH1A1HPGD | |
| SCHEMBL28049655 | 0.91 | GPR84 (0.70) | PTGS2CYP3A4GPR84ALDH1A1HPGD | |
| SCHEMBL28161011 | 0.89 | GPR84 (0.68) | PTGS2CYP3A4GPR84ALDH1A1HPGD | |
| SCHEMBL1690036 | 0.85 | PTGS2 (0.91) | PTGS2CYP3A4GPR84ALDH1A1HPGD | |
| SCHEMBL289972 | 0.85 | GPR84 (0.87) | PTGS2CYP3A4GPR84ALDH1A1HSD17B10 | |
| SCHEMBL16050465 | 0.85 | GPR84 (0.62) | PTGS2CYP3A4GPR84ALDH1A1HPGD | |
| SCHEMBL6536156 | 0.83 | PTGS2 (0.91) | PTGS2CYP3A4GPR84ALDH1A1HSD17B10 | |
| SCHEMBL11782606 | 0.83 | PTGS2 (0.91) | PTGS2CYP3A4GPR84ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11267779-B2 | Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis | PROMETIC PHARMA SMT LIMITED (GB) | 2022-03-08 | — | — | US | disclosed |
| US-11185521-B2 | Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis | Liminal Biosciences Limited (GB) | 2021-11-30 | — | — | US | disclosed |
| US-11185521-B2 | Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis | Liminal Biosciences Limited (GB) | 2021-11-30 | — | — | US | disclosed |
| CN-107106526-B | Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration | 普罗米蒂克医药SMT有限公司 | 2021-05-28 | — | — | CN | disclosed |
| US-20210085626-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TISSUE SELF-REPAIR AND REGENERATION | LIMINAL BIOSCIENCES LTD (GB) | 2021-03-25 | — | — | US | disclosed |
| US-20210085626-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TISSUE SELF-REPAIR AND REGENERATION | LIMINAL BIOSCIENCES LTD (GB) | 2021-03-25 | — | — | US | disclosed |
| US-20210002202-A1 | Substituted Aromatic Compounds and Pharmaceutical Uses Thereof | PROMETIC BIOSCIENCES, INC. (CA) | 2021-01-07 | — | — | US | disclosed |
| US-20210002202-A1 | Substituted Aromatic Compounds and Pharmaceutical Uses Thereof | PROMETIC BIOSCIENCES, INC. (CA) | 2021-01-07 | — | — | US | disclosed |
| US-10869849-B2 | Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration | Liminal Biosciences Limited (GB) | 2020-12-22 | — | — | US | disclosed |
| US-10869849-B2 | Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration | Liminal Biosciences Limited (GB) | 2020-12-22 | — | — | US | disclosed |
| US-20130217645-A1 | Compounds and Compositions for the Treatment of Cancer | PROMETIC BIOSCIENCES INC. (CA) | 2013-08-22 | — | — | US | disclosed |
| US-20130217645-A1 | Compounds and Compositions for the Treatment of Cancer | PROMETIC BIOSCIENCES INC. (CA) | 2013-08-22 | — | — | US | disclosed |
| WO-2012097427-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | PROMETIC BIOSCIENCES INC. (CA) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012097427-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | PROMETIC BIOSCIENCES INC. (CA) | 2012-07-26 | — | — | WO | disclosed |
| US-20120088784-A1 | Substituted Aromatic Compounds and Pharmaceutical Uses thereof | PROMETIC PHARMA SMT LIMITED (GB) | 2012-04-12 | — | — | US | disclosed |
| US-20120088784-A1 | Substituted Aromatic Compounds and Pharmaceutical Uses thereof | PROMETIC PHARMA SMT LIMITED (GB) | 2012-04-12 | — | — | US | disclosed |
| US-20120088784-A1 | Substituted Aromatic Compounds and Pharmaceutical Uses thereof | PROMETIC PHARMA SMT LIMITED (GB) | 2012-04-12 | — | — | US | disclosed |
| EP-2427416-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | ProMetic BioSciences Inc. (CA) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010127440-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | PROMETIC BIOSCIENCES INC. (CA) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010127440-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | PROMETIC BIOSCIENCES INC. (CA) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210085626-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TISSUE SELF-REPAIR AND REGENERATION | COL1A1, CCNH, COL2A1 | PTGS2 322/4885CYP3A4 2227/4885GPR84 1983/4885 |
| US-20130217645-A1 | Compounds and Compositions for the Treatment of Cancer | DCK, TOP2B, TOP2A | PTGS2 2852/4885CYP3A4 1284/4885GPR84 4379/4885 |
| US-20210002202-A1 | Substituted Aromatic Compounds and Pharmaceutical Uses Thereof | TYR, PAH, REN | PTGS2 613/4885CYP3A4 101/4885GPR84 1684/4885 |
| US-10869849-B2 | Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration | COL1A1, CCNH, COL2A1 | PTGS2 322/4885CYP3A4 2227/4885GPR84 1983/4885 |
| US-11185521-B2 | Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis | ADIPOR1, ADIPOR2, FN1 | PTGS2 2609/4885CYP3A4 3272/4885GPR84 632/4885 |
| US-20120088784-A1 | Substituted Aromatic Compounds and Pharmaceutical Uses thereof | TYR, PAH, REN | PTGS2 613/4885CYP3A4 101/4885GPR84 1684/4885 |
| US-11267779-B2 | Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis | PAH, HRH3, CFH | PTGS2 1591/4885CYP3A4 859/4885GPR84 1263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.